Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593753 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL29866225 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL721150 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL27657195 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL15271352 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11810215 | 0.89 | ADRB2 (0.73) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL4684534 | 0.89 | ADRA1A (0.71) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL594467 | 0.86 | ADRB2 (0.70) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL594466 | 0.86 | ADRB2 (0.70) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| Salmefamol SCHEMBL20285629 | 0.85 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2043599-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| EP-1732512-A4 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1729724-A4 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2008005692-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| WO-2008005053-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| WO-2008005691-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| JP-2007517067-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20070020299-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | claimed |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | claimed |
| US-20070020196-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | claimed |
| EP-1732512-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1729724-A1 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005065435-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. ET AL. (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005065649-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER Ϝ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | DEY, L.P. | 2004-02-05 | — | — | US | claimed |
| EP-3520779-B1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | IL5, CHRM3, NOX5 | ADRB2 19/4885ADRB1 24/4885ADRB3 17/4885 |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | STS, RORC, HSD11B1 | ADRB2 443/4885ADRB1 250/4885ADRB3 525/4885 |
| US-20070020196-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension | SAE1, STS, PDCD2L | ADRB2 1161/4885ADRB1 815/4885ADRB3 1473/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | ADRB2 1076/4885ADRB1 805/4885ADRB3 1392/4885 |
| US-20070020299-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885ADRB1 805/4885ADRB3 1392/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 6/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.